TuHURA Biosciences, Inc. (HURA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.14+1.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Address Nasdaq minimum bid price compliance: bid $2.14 vs $1.00.
TuHURA has a $50 million credit line to fund work until 2028. The company is working to meet Nasdaq rules after a delisting warning. Its new loans help keep operations going. If it solves these issues, it can develop its cancer treatments.
TuHURA is losing money and missed earnings twice recently. The stock fell nearly 29% from its high. It faces risks from debt and Nasdaq compliance. These problems could stop progress and hurt the stock.
The market is selling off TuHURA shares sharply. No clear consensus growth or fair value is priced in. The price reflects high risk and uncertainty about the turnaround.
Breaks if: credit facility falls below $50 million or is lost before 2028
TuHURA has secured a $50 million revolving credit facility to fund operations and development programs.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, as recent performance has been weak and management execution has been volatile.
The market appears to have priced in significant uncertainty, given that HURA is loss-making and operates in a high-risk environment. Expectations may be low, especially following recent negative signals and weak financial performance compared to peers.
Management is focused on advancing clinical programs and maintaining financial runway, but cash burn remains a concern. The trajectory of clinical development is on track, but recent financial results have been disappointing.
The long-term thesis hinges on management's ability to achieve key clinical milestones and secure orphan drug designations. Additionally, broader sector performance and economic conditions, such as job growth, will significantly impact HURA's outlook.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$0.56 in FY27
Breaks if: failure to regain Nasdaq compliance leading to delisting
TuHURA is addressing compliance with Nasdaq's minimum bid price requirement after receiving a delisting notice.
In the next 1 to 3 years, HURA's success will depend on its clinical advancements and market conditions. Not investment advice.